ABSTRACT
Objective: To give a retrospective bibliometric analysis of documents about the breast cancer stem cell (BCSC) and reveal the hotspots and trends of global output. Methods: Articles about the research of BCSC between 2014 and 2019 were retrieved in PubMed and Scopus databases, and SciVal was used to evaluate the global scholarly output and identify the most active factors, such as publications, countries, institutions, and top journal percentile, from the indicators of Field-Weighted Citation Impact (FWCI), CiteScore (CS), keywords and topic prominence percentile. Research hotspots and trends were discussed in detail. Results: A total of 4 700 publications on the research of BCSC from 2014 to 2019 were retrieved in this study with FWCI 1.73. The USA was the top country with a total of 1 742 publications and National Institutes of Health was the top institution both in total citation and FWCI. Non-coding RNA (ncRNA), mesenchymal stem cells, and immunotherapy were the most frequently used topics in BCSC. Conclusion: Researches on the correlation of BCSC and ncRNA, tumor microenvironment, and immunotherapy are the hotspots and trends in BCSC.
ABSTRACT
Objective To explore the potential of breast cancer stem cells in differentiating into vascular endothelial cells and participating in the angiogenesis of breast tumor.Methods The expressions of mutant P53, CD31 ,VEGF and Her-2 amplification in tumor blood vessels were detected and the single cell suspension of breast cancer was prepared.CD44+/CD24-/low cells were selected and cultured in culture system.The expressions of CD31 and CD105 on endothelial cell surface were detected by EGM-2 endothelial cell culture medium.The ability of uptake of acetylated low-density lipoprotein was measured.The endothelial cells were cultured in vitro to observe their vascular structure.Results The expressions of CD31,VEGF and mutant P53 were found in paraffin sections of breast cancer tissue samples, and they were arranged along the vessel lumen or blood vessel sphere. Immunofluorescence showed that CD31 and DAPI signals were expressed intravascularly in breast cancer tissues. Four samples of Her-2 positive amplification and 9 cases of non-amplification were detected in the samples.The successful separation of breast cancer stem cells was carried out by immunomagnetic sorting.The percentage of CD44+ cells in the pre-sorting cells was (7.5±2.6)% and that of CD44+ cells was about (94.3±4.7)% after magnetic sorting (P<0.05).The ratio of CD24+ cells was (48.2±9.4)% before sorting,and that of CD24+ cells was (4.3±1.6)% after immunomagnetic bead sorting.The proportion of CD105+ cells in mammary gland cells was (4.5±0.9)% and the proportion of CD31+ cells was (6.2±1.3)%.After cultured for three generations,the percentages of CD105+ cells and CD31+ cells were (79.6±9.3)% and (84.1±10.7)%,respectively (P<0.05). DiL-Ac-LDL could be phagocytized by endothelial cells cultured in endothelial cell culture system.Vessel-like structure was found in the endothelial cell group while the control group did not have the tendency of vascular changes.Conclusion Breast cancer stem cell-derived endothelial cells differentiate into endothelial cells in vitro and have the ability of vascular formation,suggesting that breast cancer stem cells may be involved in the formation of tumor blood vessels.
ABSTRACT
Aims: Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells. CSCs represent a minor subset of cells in the tumor and are thought to be the reason for the initiation of disease, resistance to cancer treatment, and the occurrence of metastasis. Therefore, breast cancer stem cells (BCSCs) targeting therapies are considered as the promising therapy for breast cancer treatment. This research aims to evaluate the tumor associated antigens presentation of dendritic cells fused with breast cancer stem cells in dendritic cells based therapies. Methodology: Human breast cancer stem cells are isolated from malignant breast tumors by enrich culture and fluorescent activated cell sorting. Human dendritic cells are isolated from umbilical cord blood by culturing CD14 monocytes in induced medium. Electrocution is used to fuse breast cancer stem cells and dendritic cells. Fusion cells are used to evaluate functions of dendritic cells (DCs) and also to stimulate T cells. Results: These findings indicate that fusion cells have the ability to present the antigens of breast cancer stem cell to T-cells, and regarding functionality. Conclusion: They appear to be very good candidates for antitumor vaccine in breast cancer.
ABSTRACT
Objective To separate the side population cells(SP) from breast cancer MCF-7 cell line,and observe its biological characteristics.Methods Flow cytometry and Hcechst 33342 dye efflux assay were used to isolate SP cells and non-SP cells from the MCF-7 cell line of human breast cancer.Tumorigenicity of the two subpopulations was observed by a soft agar cloning method.Results The results of FACS analysis indicated that (6.5 ± 0.4 ) ％of the MCF-7 cells were SP cells;The vitro colony formation rate of SP cells was(38.5 ±9.4)％,and higher than that of non-SP cells ( 8.4 ± 2.6 ) ％ ( t =5.34,P ＜ 0,05 ).Concluslon The SP cells sorted from MCF-7 cell line enriched tunor stem cells,which exhibited high tumorigenicity.It indicated that SP cells should play a principal role in breast cancer.
ABSTRACT
Cancer stem cells are considered as an origin of cancer. Cancer stem cells can cause tumors in mice models. Recent studies proved the efficacy of some promising therapies to treat cancers. Dendritic cell (DC) therapy is one of the best promising therapies to treat cancer. In recent years, DC therapy is performed by using primed cancer cell antigens of DC to immune organism body. This research aims to combine DC therapy with cancer stem cell antigen for treating breast cancer in murine models. DCs were derived from mouse bone marrow monocytes. Then they were primed with the breast cancer cell antigen prior to employ into the tumor mice model. This was performed to determine whether the DCs would capture and eventually migrate, be present in the spleen and present the cancer antigens to autologous CD8 T cells; induce the activation of the CTL response. The existence of tumors in mice was evaluated after 15-60 days from transplantation. The results showed that 40% mice of the experimental group, with injected breast cancer stem cell antigen loaded DCs, got tumors after 18 transplantation days. But in control group 100% mice got tumors after 15 transplantation days. It is also noticed that transplanted DCs could migrate into spleen, stimulate CD8 T cells and CD45 T cells proliferation. Specially, the ratio of CD8 T cells strongly increased in comparison to control or normal mice. These results are important and provides most required initial platform to do further experiment. Results of this study also established a promising novel targeting therapy for cancer, especially for breast cancer.